Novel Asthma Vaccine Candidate
Inventors: Dale Umetsu, Rosemarie DeKruyff, Ya-Jen Chang, Petr Illarionov
Invention Types: Therapeutics
Research Areas: Allergy/Respiratory/Pulmonary Disease, Immunology, Inflammation
Keywords: Chronic Disease, Pediatric, VaccineFor More Information Contact: Meyer, Abbie
Dr. Umetsu and his colleagues have shown that following infection of mice with influenza A virus, the incidence and severity of induced asthma is reduced. The mechanism in the lung is due to the expansion of a protective subset of natural killer T (NKT) cells, rather than of the pro-inflammatory variety. He and his colleagues have identified specific glycolipids that activate and expand the same beneficial NKT cells, including one isolated from H. pylori. Dosing the mouse by these specific glycolipids is protective.
''In the absence of influenza A or the H. pylori compound, we see an expansion of NKT cells that cause asthma and allergies,'' says Umetsu. ''We're now trying to understand how to specifically activate the inhibitory subset of NKT cells. Treatments focused on specifically expanding this inhibitory subset of cells in children might prevent the development of asthma.''
- Preventative Asthma vaccine candidate comprised of glycolipid compounds
- Asthma therapeutic candidate comprised of glycolipid compounds
- Oral administration
- Preventative treatment
- Unlikely to induce adverse side effects
- Avoids need for chronic therapies to manage asthma symptoms
- Increase in patient population and patient awareness are driving up market demand
Exclusive License, Sponsored Project and Collaboration
Key Publications: Chang YJ, Kim HY, Albacker LA, et al. Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity. J Clin Invest. 2011 Jan;121(1):57-69.
Chuang YT, Leung K, Chang YJ, et al. A natural killer T-cell subset that protects against airway hyperreactivity. J Allergy Clin Immunol. 2018 May 29. pii: S0091-6749(18)30769-3.
Related Publications: US 9,657,046 B2